Director-Affiliated Fund Sells $7.4M in Opus Genetics Stock
IRD has more than doubled off its 52-week low of $0.901.
Summary
A director-affiliated institutional fund sold $7.395 million worth of Opus Genetics common stock in an open market transaction, representing a significant reduction in its holdings.
Key Events · Ownership and Investor Activity · IRD
-
Significant Insider Sale
Foundation Fighting Blindness Retinal Degeneration Fund, an entity with director representation, sold 1,700,000 shares of common stock for $7,395,000.
-
Large Stake Reduction
This sale represents approximately 2.05% of the company's market capitalization and reduces the fund's direct holdings to 3,792,171 shares.
-
Follows Recent Financing & Losses
The sale occurs after Opus Genetics reported a substantial Q1 2026 net loss and secured new financing packages, including a $35 million tranche in April.
Analysis · IRD · Life Sciences
Foundation Fighting Blindness Retinal Degeneration Fund, an institutional investor with director representation on the board, sold 1.7 million shares for $7.395 million. This significant sale, representing over 2% of the company's market capitalization, could be interpreted as a reduction in conviction by a major institutional holder. This follows a period of significant financing activities and a substantial Q1 net loss reported by Opus Genetics.
At the time of this filing, IRD was trading at $4.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $361.4M. The 52-week trading range was $0.90 to $5.81. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.